EDI-OCT and CVI findings can shed light on choroidal vascular physiology following COVID-19 pneumonia

News
Article

Investigators measured the choroidal structures using enhanced depth imaging optical coherence tomography

Images of a chest X-ray and a CT scan show the chest and vascular system following a COVID-19 infection. Image credit: ©samunella – stock.adobe.com

The patients who had recovered from COVID-19 pneumonia had significantly higher values in the mean total choroidal area, the stromal area and the luminal area. Image credit: ©samunella – stock.adobe.com

Researchers from Istanbul, Turkey, conducted a study that found that the choroidal vascularity index (CVI) can shed light on the choroidal vascular physiology in patients who had had mild COVID-19 pneumonia and recovered completely,1 reported Muge Toprak, MD, and colleagues. Toprak is from the Kocaeli City Hospital, Istanbul. They published their findings in International Ophthalmology.

A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia (group one, COVID group) were included along with 45 healthy individuals (group two, healthy control group).

All fully recovered patients were evaluated 6 months after the pneumonia resolved. The investigators measured the choroidal structures using enhanced depth imaging optical coherence tomography (EDI-OCT). The primary measurement of interest was the CVI, which the investigators defined as the ratio of the luminal area to the total choroidal area.

The patients who comprised group one (COVID group) had significantly higher values compared to the healthy group two controls in the mean total choroidal area, the stromal area and the luminal area. There was no difference in the CVI between the two groups (P = 0.080).

Based on their findings, the investigators concluded that the CVI can reveal the choroidal vascular physiology in patients who have fully recovered from COVID-19 pneumonia. The EDI-OCT technology can be used to evaluate choroidal vascular alterations and thereby serve as a non-invasive indicator for early vascular impairment following SARS-CoV-2 infection.

Reference

1. Toprak M, Kesim E, Karasu B, Celebi ARC. Choroidal vascularity index findings in patients recovered from mild course COVID-19 pneumonia.Int Ophthalmol. 2025;45:84. https://doi.org/10.1007/s10792-025-03450-4
Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
© 2025 MJH Life Sciences

All rights reserved.